Prasad R, Mathur P P, Taneja V K, Jagota S C
Clin Ther. 1985;7(2):164-8.
One hundred sixteen children between 2 and 15 years of age entered a clinical trial of albendazole after examination of their stools revealed ova of one or more intestinal helminths. The drug was administered as a single 400-mg dose (20 ml of 2% suspension) to all the patients except those having Hymenolepis nana infection, who received treatment for three consecutive days. The stools were reexamined on days 7 and 14 posttreatment and after three months for Taenia infections. Patients were considered cured if all parasitological examinations of the feces were negative after treatment. After a single oral dose, albendazole was highly effective in ascariasis (91.9%), ancylostomiasis caused by Ancylostoma duodenale (87.2%), and H nana infection (71.4%). The drug was well tolerated, and no abnormalities were observed in hematological or blood chemistry values. Since the drug is safe and effective as a single-dose treatment of common helminthic infections, it should be considered for mass therapy in the community.
116名2至15岁的儿童在粪便检查发现一种或多种肠道蠕虫虫卵后进入了阿苯达唑的临床试验。除了感染微小膜壳绦虫的患者连续三天接受治疗外，所有患者均服用单一剂量400毫克（20毫升2%的混悬液）的药物。在治疗后第7天和第14天以及三个月后复查粪便以检测绦虫感染情况。如果治疗后所有粪便寄生虫学检查均为阴性，则认为患者已治愈。单次口服给药后，阿苯达唑对蛔虫病（91.9%）、十二指肠钩虫引起的钩虫病（87.2%）和微小膜壳绦虫感染（71.4%）非常有效。该药物耐受性良好，血液学或血液化学指标未观察到异常。由于该药物作为常见蠕虫感染的单剂量治疗安全有效，因此应考虑在社区进行群体治疗。
